"The Sanford Project: T-Rex Study", a collaborative study between Sanford Health and Caladrius Biosciences, Inc., for adolescents with newly onset type 1 diabetes has examined the body's ability to type fight 1 diabetes using cell therapy on its first participant.
Type 1 diabetes, an autoimmune disease characterized by a loss of insulin-producing beta cells, is the focus of The Sanford Project, a cornerstone research initiative at Sanford Research.
‘The Sanford Project has enrolled its first patient for conducting the clinical trial on a cell therapy using regulatory T cells, or Treg cells to treat type 1 diabetes. ’
AdvertisementInvestigators in this trial are studying the effectiveness of cell therapy with expanded regulatory T cells, or Treg cells, to treat type 1 diabetes. Treg cells regulate the body's immune system. A participant's own Treg cells are extracted from the body, purified and multiplied and returned to blood circulation. Researchers are monitoring if beta cells and insulin production can be preserved through this type of immunotherapy.
"The enrollment of the first patient in The Sanford Project: T-Rex Study demonstrates Sanford''s commitment to bringing cutting-edge research and next generation treatments to our region." said Kurt Griffin, director of clinical trials for The Sanford Project. "Leveraging the body's own natural mechanisms is a particularly appealing approach."
Participants in The Sanford Project: T-Rex Study must be 12 to 17 years old and have been diagnosed with diabetes in approximately the last two months.
PVibrio Cholerae Strains Much More Diverse Than Previously Thought Fresh Fruits Can Cut Heart Disease Risk in China M
You May Also Like